DE69833949D1 - Mutierte klasse-i-mhc-moleküle - Google Patents

Mutierte klasse-i-mhc-moleküle

Info

Publication number
DE69833949D1
DE69833949D1 DE69833949T DE69833949T DE69833949D1 DE 69833949 D1 DE69833949 D1 DE 69833949D1 DE 69833949 T DE69833949 T DE 69833949T DE 69833949 T DE69833949 T DE 69833949T DE 69833949 D1 DE69833949 D1 DE 69833949D1
Authority
DE
Germany
Prior art keywords
mhc molecules
mutated class
class
mutated
beta2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69833949T
Other languages
English (en)
Other versions
DE69833949T2 (de
Inventor
David N Garboczi
Juergen B Walter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69833949D1 publication Critical patent/DE69833949D1/de
Publication of DE69833949T2 publication Critical patent/DE69833949T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Removal Of Specific Substances (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE69833949T 1997-08-29 1998-08-20 Mutierte klasse-i-mhc-moleküle Expired - Lifetime DE69833949T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US920413 1997-08-29
US08/920,413 US6248564B1 (en) 1997-08-29 1997-08-29 Mutant MHC class I molecules
PCT/US1998/017308 WO1999011775A1 (en) 1997-08-29 1998-08-20 Mutant mhc class i molecules

Publications (2)

Publication Number Publication Date
DE69833949D1 true DE69833949D1 (de) 2006-05-11
DE69833949T2 DE69833949T2 (de) 2007-02-22

Family

ID=25443710

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833949T Expired - Lifetime DE69833949T2 (de) 1997-08-29 1998-08-20 Mutierte klasse-i-mhc-moleküle

Country Status (5)

Country Link
US (1) US6248564B1 (de)
EP (1) EP1017799B1 (de)
AT (1) ATE321131T1 (de)
DE (1) DE69833949T2 (de)
WO (1) WO1999011775A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521197B2 (en) 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
GB2339782A (en) * 1998-06-05 2000-02-09 Philip Michael Savage Chimeric protein complexes comprising HLA class I antigens
US7264965B2 (en) 1998-06-05 2007-09-04 Alexis Biotech Limited Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
FR2798128B1 (fr) * 1999-09-06 2001-11-16 Inst Nat Sante Rech Med Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla
US20040209314A1 (en) 1999-09-06 2004-10-21 Institut National De La Sante Et De La Recherche Medicale France Means for detection and purification of CD8+ T lymphocyte populations specific to peptides presented in the context of HLA
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2001072768A2 (en) * 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
US8022190B2 (en) * 2001-06-19 2011-09-20 Technion Research & Development Foundation Ltd. Immuno-molecules containing viral proteins, compositions thereof and methods of using
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
AU2003284162A1 (en) * 2002-10-28 2004-05-25 Genzyme Corporation Anti-hiv (sl9) compounds
WO2004078137A2 (en) * 2003-03-04 2004-09-16 Greenville Hospital System Antitumor agents comprising a targeting portion and an immune response triggering portion
WO2004087058A2 (en) * 2003-03-28 2004-10-14 Vaccinex, Inc. Targeted mhc class i alpha3 vaccine delivery systems
WO2005099361A2 (en) * 2003-07-10 2005-10-27 Vaccinex, Inc. MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
ES2579805T3 (es) * 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1982176A1 (de) * 2006-01-30 2008-10-22 Dako Denmark A/S Quantifizierung antigenspezifischer t-zellen in vollblut mit hoher geschwindigkeit mittels durchflusszytometrie
EP2614839A3 (de) 2006-04-05 2015-01-28 Genentech, Inc. Verfahren zur Verwendung von BOC/CDO zur Modulation der Hedgehog-Signalisierung
EA200870555A1 (ru) * 2006-05-19 2009-04-28 Тева Фармасьютикал Индастриз, Лтд. Слитые белки, их применение и способы их получения
GB2442048B (en) * 2006-07-25 2009-09-30 Proimmune Ltd Biotinylated MHC complexes and their uses
EP2102355B1 (de) * 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Proteine und peptide mit langer wirkung sowie verfahren zu ihrer herstellung und verwendung
CA2678618C (en) * 2007-02-21 2019-03-12 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cd1d molecules
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3023436A1 (de) 2007-07-03 2016-05-25 Dako Denmark A/S Verbesserte verfahren zur herstellung, markierung und verwendung von mhc-multimeren
SG183023A1 (en) * 2007-07-16 2012-08-30 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
RU2557319C2 (ru) 2007-07-16 2015-07-20 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
EP2197908A2 (de) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc-multimere in tuberkulose-diagnostika, -impfstoff und therapeutika
ES2450755T3 (es) * 2007-10-19 2014-03-25 Genentech, Inc. Anticuerpos anti-TENB2 modificados por ingeniería genética con cisteína, y conjugados de anticuerpo y fármaco
CN102083460A (zh) 2008-01-18 2011-06-01 米迪缪尼有限公司 用于位点特异性偶联的半胱氨酸工程化抗体
WO2009099728A1 (en) 2008-01-31 2009-08-13 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
WO2010009735A2 (en) * 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
AU2010203451B2 (en) 2009-01-08 2016-06-30 Albert Einstein College Of Medicine, Inc. Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
WO2010106535A1 (en) 2009-03-15 2010-09-23 Technion Research And Development Foundation Ltd. Soluble hla complexes for use in disease diagnosis
BRPI1012560A2 (pt) 2009-04-01 2016-07-26 Genentech Inc anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
RU2587621C2 (ru) 2009-04-01 2016-06-20 Дженентек, Инк. АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
MX2012006072A (es) 2009-11-30 2012-07-23 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores.
KR20130004579A (ko) 2010-02-23 2013-01-11 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
BR112012028010A2 (pt) 2010-05-03 2017-09-26 Genentech Inc anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP3406347A3 (de) 2012-02-27 2019-02-13 Amunix Operating Inc. Xten-konjugat-zusammensetzungen und verfahren zur herstellung davon
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
DK3083689T3 (da) 2013-12-17 2020-08-03 Genentech Inc Anti-CD3-antistoffer og fremgangsmåder til anvendelse
CN107108724A (zh) 2014-09-12 2017-08-29 豪夫迈·罗氏有限公司 半胱氨酸改造抗体和缀合物
AU2015320678B2 (en) 2014-09-23 2021-07-22 Genentech, Inc. Method of using anti-CD79b immunoconjugates
JP6871874B2 (ja) 2015-06-16 2021-05-19 ジェネンテック， インコーポレイテッド ＦｃＲＨ５に対するヒト化親和性成熟抗体及び使用方法
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
US11129872B2 (en) 2016-08-11 2021-09-28 Kite Pharma, Inc. Methods of making and using soluble MHC molecules
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
EP3719033A1 (de) * 2019-04-02 2020-10-07 imusyn GmbH & Co. KG Stabilisiertes mhc i
CN114174341A (zh) 2019-07-08 2022-03-11 英凯尔生物科技有限责任公司 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体、免疫缀合物和使用方法
CN114901699A (zh) 2019-09-11 2022-08-12 英凯尔生物科技有限责任公司 抗丝氨酸蛋白酶抑制剂kazal(spik)抗体的表位
EP4077391A1 (de) 2019-12-18 2022-10-26 Teneofour, Inc. An cd38 bindende, schwerkettige antikörper
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2860875D1 (en) 1977-09-28 1981-10-15 Nat Res Dev Immunological preparations incorporating mhc antigens and their production
DE3063736D1 (en) 1979-03-27 1983-07-21 Nat Res Dev Improvements in or relating to immunological preparations
US4698420A (en) 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
US5153265A (en) 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5130297A (en) 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide
DE3825615A1 (de) 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells

Also Published As

Publication number Publication date
DE69833949T2 (de) 2007-02-22
EP1017799A1 (de) 2000-07-12
WO1999011775A1 (en) 1999-03-11
ATE321131T1 (de) 2006-04-15
US6248564B1 (en) 2001-06-19
EP1017799A4 (de) 2004-08-04
EP1017799B1 (de) 2006-03-22

Similar Documents

Publication Publication Date Title
ATE321131T1 (de) Mutierte klasse-i-mhc-moleküle
DE60010098D1 (de) 28-epirapaloge
MY108864A (en) Peptide-carbohydrate conjugates generating t-cell immunity
DE59903442D1 (de) Azidfreie, gaserzeugende Zusammensetzung
CY1117235T1 (el) Νεϊσσεριακες συνθεσεις συνδυασμου
ATE296105T1 (de) Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel
DE69730202D1 (de) Azidfreie, gaserzeugende zusammensetzungen
CY1106789T1 (el) Γενικος φορεας για στοχευση μοριων σε κυτταρα που εκφραζουν gb3 υποδοχεα
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
PT996668E (pt) Composicoes aquosas termofixas
DE122004000025I2 (de) Borons{ure-und-esterverbindungen, deren Systhese und Verwendungen
SE9702773D0 (sv) Novel compounds
BG105028A (en) Bridged indenopyrrolocarbazoles
CY1108526T1 (el) Εμβολια εναντι καρκινων
DE59902827D1 (de) Azidfreie, gaserzeugende Zusammensetzung
DE19981910T1 (de) Gasbildende Zusammensetzung
NO20031860D0 (no) Kahalaolid F
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
BR0115065A (pt) Dispositivo de radiotelefonia formatável
DE50010265D1 (de) Azidfreie gaserzeugende Zusammensetzung
ATE280588T1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
BG106316A (en) Ambroxol-containing lozenge
ES2156021T3 (es) Composiciones que comprenden un derivado de dibenzoilmetano y un polimero poliamina.
TR199701298T1 (xx) Tetralinler.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition